Keywords: OAC; Oral anticoagulant; VKA; Vitamin K antagonist; DOAC; Direct oral anticoagulant; PCC; Prothrombin complex concentrate; 4F-PCC; Four factor PCC; 3F-PCC; Three factor PCC; aPCC; Activated PCC; FFP; Fresh frozen plasma; AF; Atrial fibrillation; TE; Throm
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: FFP; Fresh Frozen Plasma; FXa; factor X activated; INR; International Normalized Ratio; NOAC; non-vitamin K antagonist oral anticoagulant; PCC; prothrombin complex concentrate; PCCa; prothrombin complex concentrate activated; RBC; red blood cells; rFVIIa;
Keywords: AASLD; Association for the Study of Liver Disease; ACLF; acute-on-chronic liver failure; AICF; accelerated intravascular coagulation and fibrinolysis; ALF; acute liver failure; aPTT; activated partial thromboplastin time; CLD; chronic liver disease; DDAVP
Keywords: deep hypothermia; moderate hypothermia; circulatory arrest; coagulopathy; transfusion; hemiarch replacement; aortic arch surgery; ASA; American Society of Anesthesiologists; CPB; cardiopulmonary bypass; DHCA; deep hypothermic circulatory arrest; DUMC; Duk
Keywords: TF; tissue factor; F; factor; CTI; corn trypsin inhibitor; hTF; human TF; PE; phycoerythrin; FPRck; D-Phe-Pro-Arg-CH2Cl; rFVIIa; recombinant FVIIa; PAR; protease activated receptor; LPS; lipopolysaccharide; RGDS; Arg-Gly-Asp-Ser; HRP; horseradish peroxida
Keywords: Anticoagulants/Administration and Dosage; Atrial Fibrillation; Drug Administration Schedule; Drug Monitoring; Thrombosis/Drug Therapy; Endoscopy; Gastrointestinal; AF; atrial fibrillation; aPTT; activated partial thromboplastin time; CrCl; creatinine clea
Treatment tailoring for factor V deficient patients and perioperative management using global hemostatic coagulation assays
Keywords: FV deficiency; Thrombin generation; ROTEM; rFVIIa; FEIBA; Global coagulation assays;
Con: Factor Concentrate Usage in Cardiac Surgery-A Paucity of Data Limits Their Universal Adoption
Keywords: coagulopathy; factor concentrates; fresh frozen plasma; rFVIIa; prothrombin complex concentrate;
Prediction of human pharmacokinetics of activated recombinant factor VII and B-domain truncated factor VIII from animal population pharmacokinetic models of haemophilia
Keywords: rFVIIa; activated recombinant factor VII; rFVIII; recombinant factor VIII; PK; pharmacokinetic; pcVPC; prediction corrected visual predictive check; IIV; inter-individual variability; RSE; relative standard error; GOF; goodness-of-fit; Allometric scaling;
A role for very low-dose recombinant activated factor VII in refractory bleeding after cardiac surgery: Lessons from an observational study
Keywords: bleeding; cardiac surgery; patient blood management; recombinant activated factor VII; safety; AMI; acute myocardial infarction; CT-EXTEM; clotting time in the extrinsic pathway by thromboelastometry; IQR; interquartile range; PCC; prothrombin complex con
Recombinant factor VIIa use in acute type A aortic dissection repair: A multicenter propensity-score-matched report from the Nordic Consortium for Acute Type A Aortic Dissection
Keywords: aorta; aneurysm; dissecting; hemorrhage; ATAAD; acute type A aortic dissection; BMI; body mass index; CI; confidence interval; COPD; chronic obstructive pulmonary disease; CPB; cardiopulmonary bypass; FFP; fresh frozen plasma; HCA; hypothermic circulatory
Efficacy of recombinant factor VIIa for severe bleeding complicated by platelet transfusion refractoriness in patients with hematologic malignancies
Keywords: rFVIIa; recombinant factor VIIa; PTR; platelet transfusion refractoriness; CR; complete responses; PR; partial response; NR; no response; CCI; corrected count increment; PI; platelet count increment; BSA; body surface area; PD; the dose of platelets trans
Recombinant activated factor VII for uncontrolled bleeding postcardiac surgery
Keywords: Bleeding; Cardiac surgery; rFVIIa;
Challenges and open issues in the management of acquired hemophilia A (AHA)
Keywords: Hemophilia; Management; rFVIIa; aPCC; Immunosuppressives; Antifibrinolytics
Combination of FVIII and low-dose rFVIIa improves haemostasis in acquired haemophilia A patients: a collaborative controlled study
Keywords: AHA; Acquired haemophilia A; APTT; activated partial thromboplastin time; rFVIIa; recombinant activated factor VII; aPCC; activated prothrombin complex concentrate; PCC; prothrombin complex concentrate; TG; thrombin generation; FVIII; factor VIII; DDAVP;
Enhanced Pharmacokinetics of Factor VIIa as a Monomeric Fc Fusion
Keywords: TF; tissue factor; sTF; soluble tissue factor; FVIIa; factor VIIa; FVIII; factor VIII, FIX, factor IX; FX; factor X; Recombinant FVIIa; rFVIIa; Bypass therapy; Prophylaxis; Hemophilia;
Coagulation Factor Concentrates Fail to Restore Alterations in Fibrin Formation Caused by Rivaroxaban or Dabigatran in Studies With Flowing Blood From Treated Healthy Volunteers
Keywords: Direct oral anticoagulants; Rivaroxaban; Dabigatran; Reversal; Prothrombin complex concentrates; Activated prothrombin complex concentrates; rFVIIa
The effects of recombinant activated factor VII dose on the incidence of thromboembolic events in patients with coagulopathic bleeding
Keywords: rFVIIa; recombinant activated factor VII; VTE; venous thromboembolism; PE; pulmonary embolism; MI; myocardial infarction; CNS; central nervous system; recombinant activated factor VII; thromboembolism; stroke; coagulopathy; trauma;
A double-blind, randomized, controlled study to explore the efficacy of rFVIIa on intraoperative blood loss and mortality in patients with severe acute pancreatitis
Keywords: ALI; acute lung injury; AP; acute pancreatitis; APACHE II; Acute Physiology and Chronic Health Evaluation II; CT; computed tomography; DIC; disseminated intravascular coagulation; ICU; intensive care unit; rFVIIa; recombinant activated Factor VII; SAP; se
Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry
Keywords: BU; Bethesda Units; CZK; Czech Koruna; rFVIIa; recombinant factor VIIa; GLM; generalized linear modelling; Haemophilia; NovoSeven®; rFVIIa; High dose; Costs; Time to treatment;
A recurrent Gly43Asp substitution in coagulation Factor X rigidifies its catalytic pocket and impairs catalytic activity and intracellular trafficking
Keywords: FX; Factor X; FXa; activated FX; RVV; Russel Viper Venom; MD; molecular dynamics; FXWT; wild type FX; FX43Asp; mutant FX; TF; tissue factor; PTWT; wild type prothrombin; rFVIIa; recombinant FVIIa; ETP; endogenous thrombin potential; RMSD; root mean square
Research ArticleEffect of recombinant Factor VIIa on outcome of acute variceal bleeding: An individual patient based meta-analysis of two controlled trials
Keywords: Acute variceal bleeding; Treatment; Outcome; Meta-analysis; Factor rVIIa; rFVIIa; recombinant Factor VIIa; ITT; intention to treat; AV; active variceal bleeders at endoscopy; AVCP; Child-Pugh score >8 and active bleeding at endoscopy; AMI; myocardial infa
Recombinant fusion protein linking factor VIIa with albumin (rVIIaÂFP): Tissue distribution in rats
Keywords: AUC; area under the curve; FVIIa; activated factor VII; HPLC; high-performance liquid chromatography; ITI; immune tolerance induction; LMW; low molecular weight; NSP; NÂsuccinimidyl[2,3-3H]propionate; QWBA; quantitative whole-body autoradiography; rFVIIa
Reversal of New, Factor-specific Oral Anticoagulants by rFVIIa, Prothrombin Complex Concentrate and Activated Prothrombin Complex Concentrate: A Review of Animal and Human Studies
Keywords: AF; atrial fibrillation; aPCC; activated prothrombin complex concentrates; BID; twice daily; Cmax; maximal plasma concentration; F; coagulation factor; FEIBA; factor eight inhibitor bypass activity; PCC; prothrombin complex concentrates; rFVIIa; activated
In vitro effects of recombinant activated factor VII on thrombin generation and coagulation following inhibition of platelet procoagulant activity by prasugrel
Keywords: Anti-platelet drugs; rFVIIa; Prasugrel; Bleeding;
Darexaban: Anticoagulant effects in mice and human plasma in vitro, antithrombotic effects in thrombosis and bleeding models in mice and effects of anti-inhibitor coagulant complex and recombinant factor VIIa
Keywords: FXa; factor Xa; PE; pulmonary thromboembolism; VT; venous thrombosis; PT; prothrombin time; aPTT; activated partial thromboplastin time; rFVIIa; recombinant factor VIIa; PCC; prothrombin complex concentrate; ACC; anti-inhibitor coagulant complex; MC; meth
Increased volume of distribution for recombinant activated factor VII and longer plasma-derived factor VII half-life may explain their long lasting prophylactic effect
Keywords: pdFVII; Plasma-derived factor VII; rFVIIa; Recombinant activated factor VII; FVII; Factor VII; NCA; Non-Compartmental Analysis; OCA; One-Compartmental Analysis; Hb; Hemoglobin; T½; Half-life; Cmax; Peak plasma concentration of a drug after administration
Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: Haemophilia registry data from the Czech Republic
Keywords: BU; Bethesda Unit(s); CI; confidence interval; CZK; Czech Koruna; GLM; Generalised Linear Model; pd-aPCC; plasma-derived activated prothrombin complex concentrate; rFVIIa; recombinant activated factor VII; SD; standard deviation; SE; standard deviation; C
Fondaparinux - data on efficacy and safety in special situations
Keywords: ACS; acute coronary syndrome; anti-Xa; anti-factor Xa activity; APS; antiphospholipid syndrome; BID; twice a day; BMI; body mass index; DVT; deep vein thrombosis; EMA; European Medicines Agency; FDA; U.S. Food and Drug Administration; FEIBA; factor eight
Efficacy of Bypassing Agents in Patients With Hemophilia and Inhibitors: A Systematic Review and Meta-Analysis
Keywords: aPCC; efficacy; hemophilia; inhibitor; meta-analysis; rFVIIa
Short CommunicationThe effect of rFVIIa on pro- and anti-inflamatory cytokines in serum and cerebrospinal fluid in a swine model of traumatic brain injury
Keywords: Tumor necrosis factor-α; Interleukin-1β; Interleukin-10; rFVIIa; TBI;
Clearance of rFVIIa and NN1731 after intravenous administration to Beagle dogs
Keywords: Antithrombin; Modelling; rFVIIa; NN1731; Clearance; Pharmacokinetics;
The molar hydrodynamic volume changes of factor VIIa due to GlycoPEGylation
Keywords: PEG, poly(ethylene glycol); rFVIIa, recombinant human coagulation factor FVIIaGlycoPEGylation; rFVIIa; Intrinsic viscosity; Molar hydrodynamic volume; Capillary viscometry
Biophysical characterisation of GlycoPEGylated recombinant human factor VIIa
Keywords: GlycoPEGylation; rFVIIa; Circular dichroism; Differential scanning calorimetry; Light scattering; Stability
Heparin affinity of factor VIIa: Implications on the physiological inhibition by antithrombin and clearance of recombinant factor VIIa
Keywords: FVIIa; Factor VIIa; TF; Tissue Factor; rFVIIa; recombinant FVIIa; LMWH; Low molecular weight heparin; UHF; Unfractionated heparin; SPR; Surface Plasmon resonance; TFPI; Tissue factor pathway inhibitor; RU; Response units;
The effect of GlycoPEGylation on the physical stability of human rFVIIa with increasing calcium chloride concentration
Keywords: rFVIIa; GlycoPEGylation; Protein aggregation; Protein unfolding; Salt effects; Ca2+;
Off-Label Recombinant Factor VIIa Use and Thrombosis in Children: A Multi-Center Cohort Study
Keywords: CCC; Complex chronic conditions; DOS; Day of service; ICD-9-CM; International Classification of Diseases Classification Codes; PHIS; Pediatric Health Information System; rFVIIa; Recombinant factor VIIa;
Neurosurgical Outcomes After Intracerebral Hemorrhage: Results of the Factor Seven for Acute Hemorrhagic Stroke Trial (FAST)
Keywords: Intracerebral hemorrhage; surgical interventions; clinical outcomes; FAST; rFVIIa
Kinetic modeling sheds light on the mode of action of recombinant factor VIIa on thrombin generation
Keywords: Coagulation; Coagulopathy; Computational modeling; rFVIIa; Therapeutic; Thrombin;
Administration of recombinant activated factor VII in the intensive care unit after complex cardiovascular surgery: Clinical and economic outcomes
Keywords: 16; 37; ICU; intensive care unit; LOS; length of stay; MUSC; Medical University of South Carolina; OR; operating room; PRBC; packed red blood cell; rFVIIa; recombinant activated factor VII; TF; tissue factor;
Patient blood management during cardiac surgery: Do we have enough evidence for clinical practice?
Keywords: 1; 2; 25; 37; ACS; acute coronary syndrome; ACT; activated clotting time; ANH; acute normovolemic hemodilution; CABG; coronary artery bypass grafting; CPB; cardiopulmonary bypass; HES; hydroxyethyl starch; ICER; incremental cost-effectiveness ratio; ICU;
Optimizing thrombelastography (TEG) assay conditions to monitor rFVIIa (NovoSeven®) therapy in haemophilia a patients
Keywords: TEG; Thromboelastography; rFVIIa; recombinant Factor VIIa; FVIII; Factor VIII; FIX; Factor IX; FX; Factor X; tPA; tissue plaminogen activator; TF; tissue factor; R-time; Reaction time; MTG; maximum thrombus generation; MA; maximum amplitude; pd-aPCC; acti
Glanzmann thrombasthenia: An update
Keywords: Glanzmann thrombasthenia; Bleeding; GPIIb/IIIa; Treatment; rFVIIa
Thrombotic Risk of Recombinant Factor Seven in Pediatric Cardiac Surgery: A Single Institution Experience
Keywords: aPTT; Activated partial thromboplastin time; AS/AI; Aortic stenosis and (or) insufficiency; CHD; Congenital heart disease; DIC; Disseminated intravascular coagulation; DKS; Damus-Kaye-Stansel; d-TGA; d-transposition of the great arteries; DVT; Deep venous
Recombinant Activated Factor VII for Massive Hemoptysis in Patients With Cystic Fibrosis
Keywords: BAE; bronchial artery embolization; CF; cystic fibrosis; rFVIIa; recombinant activated factor VII; TF; tissue factor;
Eficacia del factor VII recombinante activado en el tratamiento de la hemorragia masiva en el postoperatorio de cirugÃa cardiaca: experiencia en 32 pacientes
Keywords: CirugÃa cardiaca; Hemorragia; Factor VII recombinante activado; rFVIIa; CoagulopatÃa; Cardiac surgery; Hemorrhage; Recombinant activated factor VII; Coagulation disorder;
The “Off-Label” Role of Recombinant Factor VIIa in Surgery: Is the Problem Deficient Evidence or Defective Concept?
Keywords: CPB; cardiopulmonary bypass; CTP; Child-Turcotte-Pugh; nFVIIa; natural plasma factor VIIa; OLT; orthotopic liver transplantation; rFVIIa; recombinant factor VIIa; TF; tissue factor;
Pro: The Role of Recombinant Factor VIIa in Cardiac Surgery
Keywords: rFVIIa; postoperative bleeding; adverse effects;
Use of recombinant activated factor VII in massive postpartum haemorrhage
Keywords: Postpartum hemorrhage; rFVIIa; Hysterectomy
Experience of recombinant activated factor VII (NovoSeven®) in the operating theatre and intensive care unit for the management of intracranial bleeding in nonhaemophilic patients
Keywords: rFVIIa; Intracranial bleeding; Operating theatre; Intensive care; Nonhaemophilic